SEC 13F Intelligence

Orbimed Advisors LLC / CRNX

Orbimed Advisors LLC’s Crinetics Pharmaceuticals In Position

Does Orbimed Advisors LLC own Crinetics Pharmaceuticals In (CRNX)? Yes — 999.0K shares worth $36M (+0.72% of its 13F portfolio) as of Q1 2026.

Position Value
$36M
Q1 2026
Shares
999.0K
% of Portfolio
+0.72%
Quarters Held
30
currently held

Position History CRNX

Reported value by quarter
Q4 ’18: $57MQ4 ’18Q1 ’19: $44MQ2 ’19: $51MQ3 ’19: $31MQ4 ’19: $51MQ4 ’19Q1 ’20: $30MQ2 ’20: $48MQ3 ’20: $43MQ4 ’20: $39MQ4 ’20Q1 ’21: $42MQ2 ’21: $56MQ3 ’21: $63MQ4 ’21: $91MQ4 ’21Q1 ’22: $70MQ2 ’22: $60MQ3 ’22: $63MQ4 ’22: $59MQ4 ’22Q1 ’23: $63MQ2 ’23: $71MQ3 ’23: $86MQ4 ’23: $59MQ4 ’23Q1 ’24: $65MQ2 ’24: $57MQ3 ’24: $54MQ4 ’24: $51MQ4 ’24Q1 ’25: $34MQ2 ’25: $33MQ3 ’25: $46MQ4 ’25: $47MQ4 ’25Q1 ’26: $36Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026999.0K$36M+0.72%
Q4 2025999.0K$47M+0.95%
Q3 20251.10M$46M+1.08%
Q2 20251.15M$33M+0.83%
Q1 2025999.0K$34M+0.80%
Q4 2024999.0K$51M+1.05%
Q3 20241.05M$54M+0.97%
Q2 20241.28M$57M+1.13%
Q1 20241.39M$65M+1.19%
Q4 20231.67M$59M+1.18%
Q3 20232.90M$86M+1.83%
Q2 20233.95M$71M+1.29%
Q1 20233.95M$63M+1.25%
Q4 20223.20M$59M+1.12%
Q3 20223.20M$63M+1.17%
Q2 20223.20M$60M+1.08%
Q1 20223.20M$70M+1.14%
Q4 20213.20M$91M+1.17%
Q3 20213.00M$63M+0.69%
Q2 20213.00M$56M+0.57%
Q1 20212.75M$42M+0.39%
Q4 20202.75M$39M+0.34%
Q3 20202.75M$43M+0.54%
Q2 20202.75M$48M+0.68%
Q1 20202.04M$30M+0.50%
Q4 20192.04M$51M+0.73%
Q3 20192.04M$31M+0.58%
Q2 20192.04M$51M+0.79%
Q1 20191.91M$44M+0.67%
Q4 20181.91M$57M+1.06%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Orbimed Advisors LLC’s full portfolio or all institutional holders of CRNX.